-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades Medpace Hldgs to Sell, Raises Price Target to $305

Benzinga·07/29/2025 12:55:59
Listen to the news
UBS analyst Dan Leonard downgrades Medpace Hldgs (NASDAQ:MEDP) from Neutral to Sell and raises the price target from $300 to $305.